Analyst stock forecast
BioMarin Pharmaceutical Forecast: $91.56 Analyst Target
Direct answer
BioMarin Pharmaceutical's average price target is $91.56.
The target implies +65.4% from the recorded current price, and the consensus rating is Buy.
The low target implies +8.4%, the high target implies +120.4%, and the range spans 112% of the current price.
Forecast evidence checked October 27, 2026.
Get free BioMarin Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $55.35
- Average price target
- $91.56
- High price target
- $122.00
- Low price target
- $60.00
- Low target gap
- +8.4%
- Target upside
- +65.4%
- High target gap
- +120.4%
- Target range width
- 112%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is BioMarin Pharmaceutical's average price target?
BioMarin Pharmaceutical's verified average price target is $91.56. The target range is $60.00 to $122.00.
How far are BioMarin Pharmaceutical's low and high targets from the recorded price?
The low target implies +8.4%, while the high target implies +120.4%.
How many analysts are included in BioMarin Pharmaceutical's consensus?
The verified consensus includes 27 analysts.
How is BioMarin Pharmaceutical's target upside or downside calculated?
The average target of $91.56 is divided by the recorded price of $55.35, then one is subtracted to produce +65.4%. This does not guarantee a future return.
When was BioMarin Pharmaceutical's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.